Home › All Companies › CADL

Candel Therapeutics, Inc. (CADL)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-04-02

Key Insights

  • Nicoletta Loggia, a director of Candel Therapeutics, Inc. (CADL), acquired 779 stock options on March 31, 2026 with an exercise price of $4.9 per share. This indicates potential confidence in the company's future performance.
  • The stock options granted to Loggia are fully vested at the time of grant, suggesting the company may be compensating directors in equity to preserve cash.
  • The transaction represents a direct ownership stake for Loggia, which could align her interests with those of other shareholders.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-04-02

Key Insights

  • Insider Joseph C. Papa acquired 2,795 stock options of Candel Therapeutics, Inc. (CADL) on March 31, 2026, exercisable at $4.114 per share until March 31, 2036.
  • The stock option grant was made in lieu of normal quarterly cash payments, indicating the insider's confidence in the company's future prospects.
  • The substantial option grant and the fact that it was fully vested at the time of issuance suggest that the insider believes the stock is undervalued and expects it to appreciate significantly in the coming years.
Sentiment: Positive Significance: 8/10
View Original Filing →
Insider Trading Filed: 2026-04-02

Key Insights

  • The reporting person, Paul B. Manning, was granted a stock option to purchase 4,618 shares of the company's common stock at an exercise price of $4.114 per share.
  • The option was granted on 03/31/2026 and will expire on 03/31/2036, with the underlying shares fully vested at the time of grant.
  • This stock option grant appears to be in lieu of normal quarterly cash payments, indicating the company may be compensating directors through equity awards.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Current Report Filed: 2026-03-12

Key Insights

  • Candel Therapeutics announced its Q4 2025 and full-year 2025 financial results, highlighting the company's progress and performance.
  • The company did not provide any forward-looking guidance or commentary on its pipeline or upcoming milestones in the 8-K filing.
  • No material changes to Candel's leadership, agreements, or other significant corporate events were reported in this 8-K filing.
Sentiment: Neutral Significance: 3/10
View Original Filing →
Annual Report Filed: 2026-03-12

Key Insights

  • Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company has licensed technology from Brigham and Women's Hospital and acquired assets from Peripagen Inc.
  • Candel has secured financing through a loan agreement with Trinity Capital Inc. and an at-the-market (ATM) offering. The company also has outstanding warrants that could provide additional funding if exercised.
  • Candel reported no revenue in 2024 and 2025, as it remains in the clinical development stage. The company's expenses are primarily related to R&D and general & administrative costs.
Sentiment: Neutral Significance: 6/10
View Original Filing →
Current Report Filed: 2026-02-23

Key Insights

  • Candel Therapeutics, Inc. has launched a public offering of 18.3 million shares of its common stock, with an additional 2.8 million shares available through an overallotment option.
  • The company plans to use the estimated $93.5 million in net proceeds to support critical launch readiness, medical affairs, pre-commercialization, and ongoing development of its lead candidate CAN-2409 for prostate and lung cancer.
  • Assuming the base offering amount, the company expects its cash and cash equivalents to fund operations and capital expenditures into the first quarter of 2028.
Sentiment: Positive Significance: 7/10
View Original Filing →
Current Report Filed: 2026-02-19

Key Insights

  • Candel Therapeutics entered into a $100 million purchase and sale agreement with RTW Investments for its prostate cancer drug CAN-2409 upon FDA approval, providing upfront capital and a tiered royalty structure.
  • The agreement includes a ratchet provision that increases the royalty rate if certain sales thresholds are not met, and a buy-out option for Candel Therapeutics in the event of a change of control.
  • Candel Therapeutics reported preliminary cash and cash equivalents of approximately $119.7 million as of December 31, 2025, indicating a strong cash position ahead of the potential FDA approval and product launch.
Sentiment: Positive Significance: 7/10
View Original Filing →
Insider Trading Filed: 2026-01-28

Key Insights

  • Francesca Barone, the Chief Scientific Officer of Candel Therapeutics, Inc., acquired 232,000 stock options with an exercise price of $6.01 and a 10-year vesting period.
  • The option grant suggests Barone's long-term commitment to the company and aligns her incentives with those of shareholders.
  • However, the large option grant may raise concerns about potential dilution for existing shareholders if exercised in the future.
Sentiment: Neutral Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-01-28

Key Insights

  • The CEO, Paul Peter Tak, has been granted a stock option to acquire 629,000 shares of the company's common stock, which will vest over 4 years. This indicates the CEO's continued commitment to the company's long-term success.
  • The stock option grant is priced at $6.01 per share, which may suggest the company's stock price is expected to appreciate in the future.
  • The filing shows that the CEO is the only reporting person, indicating a highly concentrated ownership structure and the CEO's significant influence over the company's operations.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-01-28

Key Insights

  • Charles Schoch, the Chief Financial Officer of Candel Therapeutics, Inc. (CADL), has been granted 232,000 stock options with a strike price of $6.01 and a 10-year expiration date. The options are subject to time-based vesting, with the shares underlying the options vesting in 48 equal monthly installments.
  • This transaction indicates that the company is incentivizing its CFO with long-term equity compensation, aligning his interests with those of the shareholders.
  • The significant number of options granted suggests that the company has confidence in the CFO's ability to drive the company's growth and performance over the next decade.
Sentiment: Positive Significance: 7/10
View Original Filing →
Insider Trading Filed: 2026-01-28

Key Insights

  • The Chief Medical Officer, William Garrett Nichols, was granted a stock option for 136,500 shares of Candel Therapeutics, Inc. (CADL) on January 26, 2026. This indicates the company's continued investment in the leadership team and aligns their interests with those of shareholders.
  • The stock option is subject to time-based vesting over a 4-year period, suggesting a long-term focus and commitment from the executive.
  • Insider transactions like this can provide insights into management's confidence in the company's future prospects and potential growth opportunities.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-01-28

Key Insights

  • Seshu Tyagarajan, the Chief Technology Officer of Candel Therapeutics, Inc. (CADL), was granted a stock option to acquire 154,000 shares of the company's common stock, representing a sizable grant that could indicate confidence in the company's prospects.
  • The option has a 10-year term and vests over 4 years in equal monthly installments, aligning Tyagarajan's interests with those of long-term shareholders.
  • The transaction occurred on January 26, 2026, suggesting recent and active management participation in the company's equity.
Sentiment: Positive Significance: 6/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.